Providing advanced medical care in a patient's home once required the help of trained professionals. No longer -- new sensor technology is enabling a massive migration from hospitals to home care environments. Read the story.
Investigators from the University of Texas MD Anderson Cancer Center tested a three-drug regimen of cladribine combined with alternating doses of cytarabine and decitabine in 118 patients with previously untreated high-risk myelodysplastic syndrome or acute myeloid leukemia age 60 or older. Results showed that 68% achieved an objective response, including 58% who experienced a complete response, as reported in the journal Lancet Haematology.
A patient at Catharina Hospital in the Netherlands was the first to undergo implantation of the Gore Excluder conformable abdominal aortic aneurysm endoprosthesis and the first to be enrolled in a post-market European registry aimed at assessing the device, W.L. Gore & Associates said. The registry will include 150 patients from up to 11 centers and will produce data for evaluating treatment success and safety of the device for treating infrarenal abdominal aortic aneurysm.
MYnd Analytics' Psychiatric EEG Evaluation Registry, a next-generation clinical phenotype database for predicting a patient's response to a medication, has been granted breakthrough device designation by the FDA. The database, a registry and reporting platform that includes more than 40,000 medication outcomes for 11,000 unique patients, enables the exchange of treatment outcome data for patients referenced to electroencephalographic neurophysiology data among health care providers.
A warning letter was issued by the FDA to an egg producer because of violations of federal law. Samuel Zimmerman's shell egg farm was found to have several violations pertaining to Salmonella enteritidis detection and prevention.
Argenx announced plans for a late-stage study to test its candidate ARGX-113, or IV efgartigimod, indicated for the treatment of primary immune thrombocytopenia, based on reports that the drug had induced clinically significant platelet count improvements in its midstage study.
Positive preliminary data will be presented by Unum Therapeutics at an upcoming medical conference on cancer immunotherapy regarding its clinical trial assessing candidate ACTR707 in combination with Roche Holding's Rituxan, or rituximab, to treat patients with relapsed/refractory CD20-positive B cell non-Hodgkin lymphoma. Unum has completed enrollment of a second dose cohort.
CRISPR Therapeutics and ViaCyte will work together to develop and market gene-edited allogeneic stem cell therapies to treat diabetes. Under the deal's terms, ViaCyte will get $15 million upfront plus a potential $10 million from CRISPR convertible debt.
Cancer Research UK has donated $18.4 million to launch the Cancer Research UK City of London Centre, which will be a virtual entity operating from its partners' offices, namely King's College London, the University College London, Francis Crick Institute and Queen Mary University of London. The initiative will focus on cancer treatment that uses living cells, such as chimeric antigen receptor T-cell therapies, and open access to about 14 million patients who could become part of their treatment research.
The USDA issued to the Office of Management and Budget a final rule regarding the National Bioengineered Food Disclosure Standard, and the Trump administration wants to put it in effect in 2020. The proposal, which includes issues such as factors and conditions that would trigger biotech labeling and the disclosure of GMO content, netted 14,018 comments.
- Page 1